Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response

Viral Immunology

Volumn 19, Issue 2, 2006, Pages 220-236

  Bettahi, Ilham ^a   Zhang, Xiuli ^a   Afifi, Rasha E ^a   Benmohamed, Lbachir ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GAMMA INTERFERON; GESTAGEN; GLYCOPROTEIN D; HERPES VACCINE; IMMUNOLOGICAL ADJUVANT; LIPOPEPTIDE; PALMITIC ACID; SODIUM CHLORIDE; SYNTHETIC PEPTIDE; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; COVALENT BOND; DENDRITIC CELL; EFFECTOR CELL; FEMALE; GENITAL HERPES; GENITAL SYSTEM DISEASE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; HERPES GENITALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; LIPOPROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; TH1 CELLS; VIRAL ENVELOPE PROTEINS;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 33745930525     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.220     Document Type: Article

References (69)

1. BenMohamed, L., Y. Belkaid, E. Loing, K. Brahimi, H. Gras-Masse, and P. Druilhe. 2002. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32:2274-2281.
2. 1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol. 77:9463-9473.
3. BenMohamed, L., H. Gras-Masse, A. Tartar, P. Daubersies, K. Brahimi, M. Bossus, A. Thomas, and P. Druilhe. 1997. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1242-1253.
4. BenMohamed, L., R. Krishnan, C. Auge, J. F. Primus, and D. J. Diamond. 2002. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106:113-121.
5. BenMohamed, L., A. Thomas, M. Bossus, K. Brahimi, J. Wubben, H. Gras-Masse, and P. Druilhe. 2000. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18:2843-2855.
6. BenMohamed, L., A. Thomas, and P. Druilhe. 2004. Long-term multiepitopic cytotoxic T lymphocytes induced in chimpanzees by combinations of Plasmodium falciparum liver stage peptides and lipopeptides. Infect. Immun. 72:11-19.
7. BenMohamed, L., S. L. Wechsler, and A. B. Nesburn. 2002. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect. Dis. 2:425-431.
8. Blower, S., A. Wald, H. Gershengorn, F. Wang, and L. Corey. 2004. Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. J. Infect. Dis. 190:1610-1617.
9. Bourel-Bonnet, L., D. Bonnet, F. Malingue, H. Gras-Masse, and O. Melnyk. 2003. Simultaneous lipidation of a characterized peptide mixture by chemoselective ligation. Bioconjug. Chem. 14:494-499.
10. Brynestad, K., B. Babbit, L. Huang, and B. T. Rouse. 1990. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. J. Virol. 64:680-685.
11. Celum, C., R. Levine, M. Weaver, and A. Wald. 2004. Genital herpes and human immunodeficiency virus: double trouble. Bull. WHO 82:447-453.
12. Chakrabarti, S., D. Pillay, D. Ratcliffe, P. A. Cane, K. E. Collingham, and D. W. Milligan. 2000. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J. Infect. Dis. 181:2055-2058.
13. Corey, L., A. G. Langenberg, R. Ashley, R. E. Sekulovich, A. E. Izu, J. M. Douglas, Jr., H. H. Handsfield, T. Warren, L. Marr, S. Tyring, R. DiCarlo, A. A. Adimora, P. Leone, C. L. Dekker, R. L. Burke, W. P. Leong, and S. E. Straus. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. J. Am. Med. Assoc. 282:331-340.
14. Danke, N. A., and W. W. Kwok. 2003. HLA class II-restricted CD4+ T cell responses directed against influenza viral antigens postinfluenza vaccination. J. Immunol. 171:3163-3169.
15. Danve-Szatanek, C., M. Aymard, D. Thouvenot, F. Morfin, G. Agius, I. Bertin, S. Billaudel, B. Chanzy, M. Coste-Burel, L. Finkielsztejn, H. Fleury, T. Hadou, C. Henquell, H. Lafeuille, M. E. Lafon, A. Le Faou, M. C. Legrand, L. Maille, C. Mengelle, P. Morand, F. Morinet, E. Nicand, S. Omar, B. Picard, B. Pozzetto, J. Puel, D. Raoult, C. Scieux, M. Segondy, J. M. Seigneurin, R. Teyssou, and C. Zandotti. 2004. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J. Clin. Microbiol. 42:242-249.
16. DeFreitas, E. C., B. Dietzschold, and H. Koprowski. 1985. Human Tlymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D. Proc. Natl. Acad. Sci. U.S.A. 82:3425-3429.
17. Deliyannis, G., D. C. Jackson, N. J. Ede, W. Zeng, I. Hourdakis, E. Sakabetis, and L. E. Brown. 2002. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J. Virol. 76:4212-4221.
18. Dudley, K. L., N. Bourne, and G. N. Milligan. 2000. Immune protection against HSV-2 in B-cell-deficient mice. Virology 270:454-463.
19. Fleming, D. T., G. M. McQuillan, R. E. Johnson, A. J. Nahmias, S. O. Aral, F. K. Lee, and M. E. St Louis. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-1111.
20. Frey, C. R., M. A. Sharp, A. S. Min, D. S. Schmid, V. Loparev, and A. M. Arvin. 2003. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J. Infect. Dis. 188:40-52.
21. Gahery, H., J. Choppin, I. Bourgault, E. Fischer, B. Maillere, and J. G. Guillet. 2005. HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach. Therapie 60:243-248.
22. Gahery-Segard, H., G. Pialoux, S. Figueiredo, C. Igea, M. Surenaud, J. Gaston, H. Gras-Masse, J. P. Levy, and J. G. Guillet. 2003. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J. Virol. 77:11220-11231.
23. Gallichan, W. S., R. N. Woolstencroft, T. Guarasci, M. J. McCluskie, H. L. Davis, and K. L. Rosenthal. 2001. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166:3451-3457.
24. Gras-Masse, H. 2001. Chemoselective ligation and antigen vectorization. Biologicals 29:183-188.
25. Harle, P., S. Noisakran, and D. J. Carr. 2001. The application of a plasmid DNA encoding IFN-alpha 1 postinfection enhances cumulative survival of herpes simplex virus type 2 vaginally infected mice. J. Immunol. 166:1803-1812.
26. Khanna, K. M., A. J. Lepisto, and R. L. Hendricks. 2004. Immunity to latent viral infection: many skirmishes but few fatalities. Trends Immunol. 25:230-234.
27. Klinguer, C., D. David, M. Kouach, J. M. Wieruszeski, A. Tartar, D. Marzin, J. P. Levy, and H. Gras-Masse. 1999. Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate. Vaccine 18:259-267.
28. Koelle, D. M., H. B. Chen, M. A. Gavin, A. Wald, W. W. Kwok, and L. Corey. 2001. CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J. Immunol. 166:4049-4058.
29. Koelle, D. M., and L. Corey. 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113.
30. Kuklin, N. A., M. Daheshia, S. Chun, and B. T. Rouse. 1998. Role of mucosal immunity in herpes simplex virus infection. J. Immunol. 160:5998-6003.
31. Kumaraguru, U., I. A. Davis, S. Deshpande, S. S. Tevethia, and B. T. Rouse. 2001. Lymphotoxin alpha-/- mice develop functionally impaired CD8+ T cell responses and fail to contain virus infection of the central nervous system. J. Immunol. 166:1066-1074.
32. Langenberg, A. G., L. Corey, R. L. Ashley, W. P. Leong, and S. E. Straus. 1999. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N. Engl. J. Med. 341:1432-1438.
33. Liu, F., R. Feuer, D. E. Hassett, and J. L. Whitton. 2003. Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8 T cell-mediated, TNF-dependent immunopathology. J. Clin. Invest. 116:465-475.
34. McDermott, M. R., J. R. Smiley, P. Leslie, J. Brais, H. E. Rudzroga, and J. Bienenstock. 1984. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J. Virol. 51:747-753.
35. Mikloska, Z., M. Ruckholdt, I. Ghadiminejad, H. Dunckley, M. Denis, and A. L. Cunningham. 2000. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J. Immunol. 164:5167-5176.
36. Milligan, G. N., D. I. Bernstein, and N. Bourne. 1998. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:6093-6100.
37. Moron, V. G., P. Rueda, C. Sedlik, and C. Leclerc. 2003. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J. Immunol. 171:2242-2250.
38. Nardin, E. H., J. M. Calvo-Calle, G. A. Oliveira, R. S. Nussenzweig, M. Schneider, J. M. Tiercy, L. Loutan, D. Hochstrasser, and K. Rose. 2001. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. J. Immunol. 166:481-489.
39. 1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23:873-883.
40. Nesburn, A. B., S. Slanina, R. L. Burke, H. Ghiasi, S. Bahri, and S. L. Wechsler. 1998. Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J. Virol. 72:7715-7721.
41. Novak, E. J., A. W. Liu, J. A. Gebe, B. A. Falk, G. T. Nepom, D. M. Koelle, and W. W. Kwok. 2001. Tetramer-guided epitope mapping: rapid identification and characterization of immunodominant CD4+ T cell epitopes from complex antigens. J. Immunol. 166:6665-6670.
42. Parr, M. B., L. Kepple, M. R. McDermott, M. D. Drew, J. J. Bozzola, and E. L. Parr. 1994. A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2. Lab. Invest. 70:369-380.
43. Pebody, R. G., N. Andrews, D. Brown, R. Gopal, H. De Melker, G. Francois, N. Gatcheva, W. Hellenbrand, S. Jokinen, I. Klavs, M. Kojouharova, T. Kortbeek, B. Kriz, K. Prosenc, K. Roubalova, P. Teocharov, W. Thierfelder, M. Valle, P. Van Damme, and R. Vranckx. 2004. The sero-epidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect 80:185-191.
44. Perng, G. C., B. Maguen, L. Jin, K. R. Mott, J. Kurylo, L. BenMohamed, A. Yukht, N. Osorio, A. B. Nesburn, G. Henderson, M. Inman, C. Jones, and S. L. Wechsler. 2002. A novel herpes simplex virus type 1 transcript (AL-RNA) antisense to the 5′ end of the latency-associated transcript produces a protein in infected rabbits. J. Virol. 76:8003-8010.
45. 1 responses during retrovirus infection in mice. J. Virol. 76:7942-7948.
46. Pialoux, G., H. Gahery-Segard, S. Sermet, H. Poncelet, S. Fournier, L. Gerard, A. Tartar, H. Gras-Masse, J. P. Levy, and J. G. Guillet. 2001. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 15:1239-1249.
47. Rodriguez-Carreno, M. P., M. S. Nelson, J. Botten, K. Smith-Nixon, M. J. Buchmeier, and J. L. Whitton. 2005. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335:87-98.
48. Rosenthal, K. S., H. Mao, W. I. Home, C. Wright, and D. Zimmerman. 1999. Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 17:535-542.
49. 1-polarized T cell priming. J. Immunol. 15:6089-6097.
50. Smith, C. M., G. T. Belz, N. S. Wilson, J. A. Villadangos, K. Shortman, F. R. Carbone, and W. R. Heath. 2003. Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J. Immunol. 170:4437-4440.
51. Stanberry, L. R., D. I. Bernstein, R. L. Burke, C. Pachl, and M. G. Myers. 1987. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155:914-920.
52. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
53. Stranska, R., R. Schuurman, E. Nienhuis, I. W. Goedegebuure, M. Polman, J. F. Weel, P. M. Wertheim-Van Dillen, R. J. Berkhout, and A. M. van Loon. 2005. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J. Clin. Virol. 32:7-18.
54. Straus, S. E., L. Corey, R. L. Burke, B. Savarese, G. Barnum, P. R. Krause, R. G. Kost, J. L. Meier, R. Sekulovich, S. F. Adair, and et al. 1994. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343:1460-1463.
55. Straus, S. E., B. Savarese, M. Tigges, A. G. Freifeld, P. R. Krause, D. M. Margolis, J. L. Meier, D. P. Paar, S. F. Adair, D. Dina, and et al. 1993. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. J. Infect. Dis. 167:1045-1052.
56. Toka, F. N., M. Gierynska, and B. T. Rouse. 2003. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1. J. Virol. 77:12742-12752.
57. Toka, F. N., M. Gierynska, S. Suvas, S. P. Schoenberger, and B. T. Rouse. 2005. Rescue of memory CD8(+) T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology 331:151-158.
58. Toka, F. N., S. Suvas, and B. T. Rouse. 2004. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. J. Virol. 78:13082-13089.
59. 1 and Th2 CD4+ T cell responses. J. Immunol. 165:6487-6495.
60. Watari, E., B. Dietzschold, G. Szokan, and E. Heber-Katz. 1987. A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2. J. Exp. Med. 165:459-470.
61. Weiss, H. 2004. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 11 (Suppl 1):24A-35A.
62. Welling-Webster, S., A. J. Scheffer, and G. W. Welling. 1991. B and T cell epitopes of glycoprotein D of herpes simplex virus type 1. FEMS Microbiol. Immunol. 3:59-68.
63. Wong, P., and E. G. Pamer. 2003. CD8 T cell responses to infectious pathogens. Annu. Rev. Immunol. 21:29-70.
64. Woodland, D. L. 2004. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25:98-104.
65. Zajac, A. J., K. Murali-Krishna, J. N. Blattman, and R. Ahmed. 1998. Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells. Curr. Opin. Immunol. 10:444-449.
66. Zeng, W., S. Ghosh, Y. F. Lau, L. E. Brown, and D. C. Jackson. 2002. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J. Immunol. 169:4905-4912.
67. Zhang, X., A. Issagholian, E. A. Berg, J. B. Fishman, A. B. Nesburn, and L. BenMohamed. 2005. Th-cytotoxic t-lymphocyte chimeric epitopes extended by nNε-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J. Virol. 79:15289-15301.
68. 1 responses to herpes simplex virus-2. J. Exp. Med. 197:153-162.
69. 1-dependent protective immunity. Eur. J. Immunol. 34:1142-1149.